And the beat goes onis a refrain that kept rolling through my head after attending the symposium Tuesday hosted by the Womens Institute for a Secure Retirement (WISER) in Washington, D.C. The topic: retirement solutions for women.
If you hear the words “Irrevocable Trust,” you probably think of an estate planning tool designed to protect assets from inheritance tax. Or maybe to protect assets for Medicaid planning purposes. But Trusts can be used in a surprising variety of ways, especially during your lifetime.
Take NBA player Michael Carter-Williams. Instead of....More>>>
Bank of America (NYSE:BAC) reported first-quarter earnings that beat analyst estimates on the top and bottom lines, but that only tells part of the story. A deeper look at the bank’s latest earnings report shows that the bank continues to improve in terms of efficiency and profitability, so here are seven key items that are important for investors to know.
The Q4 2016 earnings report for small cap mobile game stock Glu Mobile Inc (NASDAQ: GLUU)is scheduled for after the market closes onWednesday (February 8). In the past, our SmallCap Network Elite Opportunity (SCN EO) portfolio had open positions in other mobile game stocks with our SCN EO newsletter notingin August 2015 before that summers market meltdown:
After four weeks without a single IPO, the US IPO market is back from its annual August pause. Four deals are on the IPO calendar to raise $690 million in the week ahead, including:
The first energy IPO in over a year, an MLP with a 7.5% annualized yield A VC-backed tech company (2016’s tech IPO class is up over +100% on average) A large Bermuda bank and wealth manager with....More>>>
Amicus Therapeutics, Inc. (NASDAQ: FOLD) is watching its shares drop on Tuesday after the company provided an update on its regulatory pathway for its Fabry Disease treatment. After the company had several collaborative discussions with the U.S. Food and Drug Administration (FDA), Amicus plans to collect additional data on gastrointestinal (GI) symptoms in Fabry patients who have an amenable mutation.
On Friday, small cap biotechArrowhead Pharmaceuticals (NASDAQ: ARWR) jumped 18.28% after hosting an investor & analyst R&D day to introduce its proprietary Targeted RNAi Molecule (TRiMTM) platform and to review its pipeline of RNAi therapeutic candidates. Arrowhead Pharmaceuticals develop